185 related articles for article (PubMed ID: 18981708)
1. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.
Arvanitis C; Bendapudi PK; Tseng JR; Gambhir SS; Felsher DW
Cancer Biol Ther; 2008 Dec; 7(12):1947-51. PubMed ID: 18981708
[TBL] [Abstract][Full Text] [Related]
2. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models.
Campanile C; Arlt MJ; Krämer SD; Honer M; Gvozdenovic A; Brennecke P; Fischer CR; Sabile AA; Müller A; Ametamey SM; Born W; Schibli R; Fuchs B
J Nucl Med; 2013 Aug; 54(8):1362-8. PubMed ID: 23801674
[TBL] [Abstract][Full Text] [Related]
5. Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [
Collantes M; Martínez-Vélez N; Zalacain M; Marrodán L; Ecay M; García-Velloso MJ; Alonso MM; Patiño-García A; Peñuelas I
BMC Cancer; 2018 Nov; 18(1):1193. PubMed ID: 30497448
[TBL] [Abstract][Full Text] [Related]
6. Staging canine patients with appendicular osteosarcoma utilizing fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography compared to whole body computed tomography.
Brody A; Crooks JC; French JM; Lang LG; Randall EK; Griffin LR
Vet Comp Oncol; 2022 Sep; 20(3):541-550. PubMed ID: 35166445
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of
Liu F; Zhang Q; Zhou D; Dong J
BMC Cancer; 2019 Apr; 19(1):323. PubMed ID: 30953476
[TBL] [Abstract][Full Text] [Related]
8. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
[TBL] [Abstract][Full Text] [Related]
9. Utilization of positron emission tomography in the management of patients with sarcoma.
Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients.
Sharp SE; Shulkin BL; Gelfand MJ; McCarville MB
Pediatr Radiol; 2017 Dec; 47(13):1800-1808. PubMed ID: 28887617
[TBL] [Abstract][Full Text] [Related]
11. Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Jain M; Arvanitis C; Chu K; Dewey W; Leonhardt E; Trinh M; Sundberg CD; Bishop JM; Felsher DW
Science; 2002 Jul; 297(5578):102-4. PubMed ID: 12098700
[TBL] [Abstract][Full Text] [Related]
12. Solitary Retroperitoneal Metastasis as the Initial Site of the Relapse of Osteosarcoma Revealed by FDG PET/CT.
Liu B; Yang H; Servaes S; Zhuang H
Clin Nucl Med; 2015 Nov; 40(11):892-4. PubMed ID: 26018716
[TBL] [Abstract][Full Text] [Related]
13. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy.
Franzius C; Sciuk J; Daldrup-Link HE; Jürgens H; Schober O
Eur J Nucl Med; 2000 Sep; 27(9):1305-11. PubMed ID: 11007511
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
16.
Oh C; Bishop MW; Cho SY; Im HJ; Shulkin BL
J Nucl Med; 2023 Jun; 64(6):842-851. PubMed ID: 37201958
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-MDP Bone Scan and 18F-FDG PET/CT Imaging of Multiple Extraskeletal Osteosarcomas.
Sun ZK; Shen CT; Qiu ZL; Luo QY
Clin Nucl Med; 2018 Nov; 43(11):e412-e413. PubMed ID: 30106862
[TBL] [Abstract][Full Text] [Related]
20. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
Du Y; Cullum I; Illidge TM; Ell PJ
J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
